一、AI的企业应用仍处于初期阶段 人工智能的2C应用进展很快，2024年美国居民生成式AI的渗透率已达39.6% （来源：圣路易斯联储） 。然 而，当前的模型厂商还热衷于评分打榜、技术炫耀，企业应用尚处于早期阶段。迫切需要找到丰富落地 场景，加快推进AI和各行各业的深度融合。 国联证券对A股上市公司财报中提及AI的情况进行了梳理，近年提及数量迅速增加，从2020年的172家 上升至2023年的超过1200家，然而在所有A股上市公司的占比仍然不高，2023年还不到20%。根据国家 经济研究局 （NBER） 数据，截止2024年2月，美国AI企业采用率仅有5.4%。根据欧盟统计局数据，2024 年欧盟各国AI企业普及率在3.1%-27.6%之间，总体为13.5%。如下图所示。各国对问题的定义和调研方 法有所不同，以上数据不能简单横向比较，但都反映出AI的企业应用还处于初期阶段。 图 2024年欧盟的AI企业普及率 来源：根据欧盟统计局数据整理，2025 闫德利 腾讯研究院资深专家 二、信息密度越高，AI应用越易越深 AI的企业应用具有明显的行业差异，它与信息密度有关。大体是信息密度越高，AI应用越容易越深入； 信 ...

Core Viewpoint - The company is actively expanding its business in HVLS fans, artificial intelligence, and smart governance, while facing challenges in revenue and profitability in the recent quarter [2][8]. Group 1: HVLS Fan Business - The HVLS fan business is the company's main revenue source, achieving a revenue of 244 million yuan in 2024 with a gross margin of 36.95% [2]. - The company holds a leading position in the domestic HVLS fan industry and aims to increase its overseas market share, which currently accounts for 23.31% of total revenue [2]. Group 2: Artificial Intelligence Initiatives - The company is leveraging its joint venture, Henan Yuzhi Kaile Intelligent Technology Co., Ltd., to advance AI applications in smart office, smart travel, and smart healthcare [3]. - The AI solutions provided are designed to ensure data security and compliance while enhancing operational efficiency [3]. Group 3: Smart Driving Collaboration - A cooperation agreement was signed with the Henan Provincial Automotive Industry Investment Group to promote digital and intelligent upgrades in the automotive sector, focusing on autonomous driving technology [4]. - The collaboration aims to develop technologies related to unmanned vehicles and logistics [4]. Group 4: Smart Governance Developments - In April 2025, the company launched a large model government integrated machine in collaboration with People's Daily Online, enhancing its offerings in smart governance [5]. - The "Deep Language Future" smart governance machine is designed for local deployment and ensures data security and compliance with government regulations [6]. Group 5: AI Medical Solutions - The AI medical segment focuses on providing various solutions for different medical applications, including smart hospital renovations and AI-assisted research platforms [7]. - Collaborations with major hospitals and health institutions are underway to enhance clinical and research capabilities using AI technologies [8]. Group 6: Financial Performance - In Q1 2025, the company reported a main revenue of 37.91 million yuan, a year-on-year decrease of 20.13%, while the net profit attributable to shareholders was -5.17 million yuan, an increase of 44.54% year-on-year [8]. - The company’s debt ratio stands at 16.59%, with investment income of 1.17 million yuan and a gross margin of 41.76% [8].

证券代码：300253 证券简称：卫宁健康 公告编号：2025-046 债券代码：123104 债券简称：卫宁转债 卫宁健康科技集团股份有限公司 本公司及董事会全体成员保证信息披露内容的真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 一、募集资金到位情况 卫宁健康科技集团股份有限公司（以下简称"公司"）经中国证 券监督管理委员会《关于同意卫宁健康科技集团股份有限公司向不特 定对象发行可转换公司债券注册的批复》 （证监许可［2021］311 号） 核准，获准向不特定对象发行可转换公司债券 970.2650 万张，每张 面 值 为 人 民 币 100 元 ， 按 面 值 发 行 ， 募 集 资 金 总 额 为 人 民 币 实际募集资金净额为人民币 961,209,622.64 元。 容诚会计师事务所（特殊普通合伙）已对公司向不特定对象发行可转 换公司债券的募集资金到位情况进行了审验，并于 2021 年 3 月 23 日 出具了"容诚验字2021200Z0016 号" 下简称"国泰君安"）分别与宁波银行股份有限公司上海黄浦支行、 上海银行股份有限公司浦西支行（以下简称"上海银行浦西支行"） 中国民生银行股 ...

Group 1 - NuraNavX, a brain science AI company, recently completed a multi-million yuan angel round financing led by K2 Venture Partners, with funds aimed at market promotion and further R&D of AI brain connectomics products [1] - The company's AI-based individualized brain network mapping, which can be understood as a "GPS for the brain," reveals how different brain regions connect, crucial for understanding complex brain diseases [1] - NuraNavX divides each patient's brain into 379 unique regions based on MRI data and has identified over 20 important brain functional networks, enabling personalized brain network maps for surgical protection and targeted treatment of central nervous system diseases like depression and anxiety [1] Group 2 - The company has established self-operated neuroregulation clinics in Shenzhen and Shanghai, providing treatments for various conditions including depression, anxiety, insomnia, and schizophrenia [2] - In addition to medical-grade products and services, NuraNavX's AI brain connectomics software supports researchers in brain science and has developed consumer-level brain health assessment reports to identify potential risks early [2]

2025.05. 26 本文字数：4795，阅读时长大约8分钟 作者 | 第一财经 钱童心 人工智能正在将临床诊疗方式从经验医学转变为由数据驱动。从影像识别、病理分析到手术机器人， AI的发展正在推动个性化治疗的发展，掀起一场"智能医学"的变革。 但这并不意味着我们不再需要有经验的医生，而是在AI的赋能下，更多的年轻医生利用技术也能提升 诊疗水平，整个医疗价值链也将被重塑。 AI能精准诊断冠心病吗 人工智能等新技术的飞速发展，正在悄然改变社会和人们的生活，在医学领域亦是如此，新技术为临 床诊疗和科学研究带来了新视野，也已经产生了不少突破性的成果。 "原本依赖医生经验与感觉判断的部分，在智能化与数字化的辅助下，边界也没有那么绝对了。"中国 科学院院士、复旦大学附属中山医院樊嘉教授在《在科技变革中，成为不可替代的你》一文中写道。 樊嘉表示，数字孪生医生已逐渐成为中山医院医疗团队中的重要成员——这些"数字分身"会对"生物 人医生"原型进行建模与仿真，而不仅仅是知识结构的复制和经验叠加。 他告诉第一财经记者，这些"数字医生"有些已经成形，例如"小葛"医生和"小白"医生，分别代表了中 山医院心内科葛均波院士及呼吸科白春 ...

Group 1: AI in Clinical Diagnosis - Artificial intelligence is transforming clinical diagnosis from experience-based medicine to data-driven approaches, enhancing personalized treatment [1][3] - AI technologies, such as digital twin doctors, are being integrated into medical teams, allowing for modeling and simulation of patient data to improve diagnosis and treatment [3][12] - A deep learning model for CT myocardial perfusion imaging has been developed to accurately assess myocardial ischemia, providing valuable quantitative metrics for doctors [6][7] Group 2: AI in Surgical Procedures - AI-assisted surgical robots are being utilized for remote surgeries, breaking geographical barriers and allowing for complex procedures to be performed from a distance [8][9] - The development of AI systems for pre-surgical planning is enabling surgeons to visualize and simulate operations, improving precision and outcomes [11][12] - AI is expected to play a significant role in the future of smart hospitals, enhancing patient monitoring and treatment planning through digital twin technology [13] Group 3: Ethical Considerations and Future Implications - The integration of AI in healthcare raises ethical questions, particularly regarding data security and the role of AI in decision-making processes [18][19] - Experts emphasize that AI should serve as a "super assistant" to doctors, enhancing their capabilities rather than replacing them, especially in areas requiring empathy and moral judgment [19] - The future of healthcare is envisioned as a collaboration between AI and human doctors, where AI alleviates repetitive tasks, allowing doctors to focus on patient care [19]

Group 1 - The 2025 Beijing Science and Technology Week and the "Automation Light" Public Science Day at the Chinese Academy of Sciences showcased innovative achievements in various fields including artificial intelligence, gene therapy, brain-machine interfaces, and hydrogen energy [1][2] - The theme of this year's Science and Technology Week is "Determined to Innovate and Build a Strong Science and Technology Nation," emphasizing the collaboration between the Chinese Academy of Sciences and Beijing to promote high-end scientific resources [2][3] - The "Automation Light" Public Science Day has successfully held 21 sessions, inspiring many young people to explore science [2] Group 2 - The event featured 18 research achievements in artificial intelligence applications across various sectors, including smart healthcare and robotics [3][5] - The Q series humanoid robots and Casia Hand dexterous hand were highlighted, showcasing their capabilities in hazardous environments and service industries [3][4] - The micro-invasive brain-machine interface technology was presented, demonstrating its potential in medical rehabilitation and neural control, with ongoing animal experiments [4][5] Group 3 - Interactive exhibitions allowed the public to experience advanced technologies, such as a desktop carotid ultrasound robot system that aids in standardized screening [5] - Attendees engaged with various interactive projects, including AI art and thought rehabilitation technologies, enhancing public understanding of cutting-edge innovations [5]

Core Viewpoint - The company has decided not to exercise the early redemption rights for its convertible bonds, despite meeting the conditions for redemption, to protect investor interests and due to existing financial commitments [2][6]. Group 1: Convertible Bond Redemption - The company's stock has met the condition of having at least 15 trading days with closing prices not lower than 130% of the current conversion price over a 30-day period from April 29, 2025, to May 22, 2025, triggering the redemption clause for the "Run Da Convertible Bonds" [2][5]. - The board of directors unanimously agreed not to redeem the "Run Da Convertible Bonds" early during a meeting held on May 22, 2025, considering current market conditions and financial arrangements [6][7]. - The company will not exercise the early redemption rights for the next three months, from May 23, 2025, to August 22, 2025, even if the redemption conditions are met again [2][6]. Group 2: Convertible Bond Issuance Overview - The company issued 5,500,000 convertible bonds on June 17, 2020, with a total amount of 55 million yuan and a maturity of six years, with varying interest rates from 0.3% to 2.0% over the term [3][4]. - The initial conversion price was set at 13.36 yuan per share, which has been adjusted multiple times due to profit distributions, currently standing at 13.10 yuan per share as of July 18, 2023 [3][4]. Group 3: Related Party Transactions - The company's actual controllers, major shareholders, and senior management have not held "Run Da Convertible Bonds" in the six months prior to the redemption conditions being met and have no plans to reduce their holdings in the next six months [7].

证券代码：301370 证券简称：国科恒泰 公告编号：2025-030 国科恒泰（北京）医疗科技股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 二、本次实施的权益分派方案 本公司 2024 年年度权益分派方案为：以公司现有总股本 470,600,000 股剔除已 回购股份 3,635,860 股后的 466,964,140 股为基数，向全体股东每 10 股派 0.840000 元人民币现金（含税：扣税后，通过深股通持有股份的香港市场投资者、境外机构 （含 QFII、RQFII）以及持有首发前限售股的个人和证券投资基金每 10 股派 0.756000 元；持有首发后限售股、股权激励限售股及无限售流通股的个人股息红利税实行差 别化税率征收，本公司暂不扣缴个人所得税，待个人转让股票时，根据其持股期限 计算应纳税额【注】；持有首发后限售股、股权激励限售股及无限售流通股的证券 投资基金所涉红利税，对香港投资者持有基金份额部分按 10%征收，对内地投资者 持有基金份额部分实行差别化税率征收）。 【注：根据先进先出的原则，以投资者证券账户为单位计算持股期限，持 ...

Core Insights - JD Health's self-developed medical model "Jingyi Qianxun" is set to launch its 2.0 version, focusing on advancing AI in healthcare through technological innovation and ecosystem openness [1][2] - The upgrade aims to enhance clinical decision-making and patient health management by transitioning from general services to more complex specialized disease areas [1][2] Group 1: Technological Advancements - The upgraded "Jingyi Qianxun" model utilizes multi-modal perception and deep retrieval technology to integrate diverse clinical information, creating a decision support system that mirrors real-world scenarios [2] - The model balances AI's certainty with the flexibility required in medical decision-making, providing doctors with a more reliable auxiliary tool to improve clinical practicality [2] Group 2: Industry Impact - Since its open-source launch in February, dozens of hospitals, health management centers, pharmaceutical retail companies, and elderly care institutions have begun using the "Jingyi Qianxun" model for service upgrades and model transformations [2] - The 2.0 upgrade represents a significant milestone for JD Health in the medical AI sector, focusing on specialized diseases, enhancing evidence-based reasoning, and expanding application scenarios [2] Group 3: Future Directions - JD Health plans to deepen collaborations with hospitals, pharmaceutical companies, and research institutions to explore the potential of AI in healthcare, aiming to balance the distribution of medical resources and extend quality healthcare services to a broader population [2]